Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Feb 13, 2019 09:42 PM IST | Source: Moneycontrol.com

Delhi HC sets aside govt ban on Lupin's diabetes drugs

Gluconorm-PG is a triple combination of diabetes drugs Glimepiride, Metformin, Pioglitazone, with sales of around Rs 50 crore.

Viswanath Pilla @viswanath_pilla

Viswanath Pilla
Moneycontrol News

In a major relief to drug maker Lupin, the Delhi High Court on February 13 set aside the ban imposed by Central government on the manufacture and sale of its fixed dose combinations (FDC) Gluconorm-PG 1 Forte and Gluconorm-PG 2 Forte, which is used in the treatment of diabetes.

Gluconorm-PG 1 Forte and Gluconorm-PG 2 Forte were part of 344 FDCs banned by the government on September 7, 2018, which exercised its powers under Section 26A of the Drugs and Cosmetics Act.

Gluconorm-PG is a triple combination of Glimepiride, Metformin, Pioglitazone, with sales of around Rs 50 crore.

The ban by the Central government was based on the report submitted by a  sub-committee of the Drug Technical Advisory Board (DTAB) on July 31, 2018.

Lupin had immediately moved to the Delhi High Court against the ban, alleging it as arbitrary and contrary to material that supports the efficacy of the FDC.

Lupin had argued that the FDCs reduce the individual dose requirement and have a rapid action on the blood glucose levels.

The triple drug can effectively reduce the use of insulin in patients suffering from type- 2 diabetes, additionally, the patients also benefit from the improved cardiovascular outcomes because of improved glycemic control, Lupin claimed.
First Published on Feb 13, 2019 09:35 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant